ZA975134B - Generation of replicative molecules in vivo. - Google Patents

Generation of replicative molecules in vivo.

Info

Publication number
ZA975134B
ZA975134B ZA9705134A ZA975134A ZA975134B ZA 975134 B ZA975134 B ZA 975134B ZA 9705134 A ZA9705134 A ZA 9705134A ZA 975134 A ZA975134 A ZA 975134A ZA 975134 B ZA975134 B ZA 975134B
Authority
ZA
South Africa
Prior art keywords
vivo
generation
molecules
replicative
replicative molecules
Prior art date
Application number
ZA9705134A
Other languages
English (en)
Inventor
Michel Perricaudet
Patrice Yeh
Helene Leblois-Prehaud
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of ZA975134B publication Critical patent/ZA975134B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/11043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
ZA9705134A 1996-06-12 1997-06-10 Generation of replicative molecules in vivo. ZA975134B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9607273A FR2749857B1 (fr) 1996-06-12 1996-06-12 Generation de molecules replicatives in vivo

Publications (1)

Publication Number Publication Date
ZA975134B true ZA975134B (en) 1997-12-31

Family

ID=9492965

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9705134A ZA975134B (en) 1996-06-12 1997-06-10 Generation of replicative molecules in vivo.

Country Status (18)

Country Link
US (1) US6630322B1 (es)
EP (1) EP0906443B1 (es)
JP (1) JP2000511779A (es)
AT (1) ATE301721T1 (es)
AU (1) AU726442B2 (es)
BR (1) BR9709700A (es)
CA (1) CA2257916A1 (es)
CZ (1) CZ296600B6 (es)
DE (1) DE69733948T2 (es)
DK (1) DK0906443T3 (es)
ES (1) ES2248849T3 (es)
FR (1) FR2749857B1 (es)
HU (1) HU224175B1 (es)
IL (1) IL127430A0 (es)
NO (1) NO985739L (es)
SK (1) SK169898A3 (es)
WO (1) WO1997047757A1 (es)
ZA (1) ZA975134B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2720756B1 (fr) * 1994-06-02 1996-07-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
FR2799472B1 (fr) 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
AU2001288839A1 (en) * 2000-09-08 2002-03-22 The General Hospital Corporation Self-rearranging dna vectors
WO2003004088A2 (en) 2001-07-05 2003-01-16 Aventis Pharma S.A. Method of administration of a gene of interest to the heart and vasculature
US7164056B2 (en) * 2002-05-03 2007-01-16 Pioneer Hi-Bred International, Inc. Gene targeting using replicating DNA molecules
EP2362912A1 (en) * 2008-11-14 2011-09-07 Life Technologies Corporation Compositions and methods for engineering cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665543A (en) * 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US6120764A (en) * 1993-06-24 2000-09-19 Advec, Inc. Adenoviruses for control of gene expression
EP0632054A1 (en) * 1993-06-28 1995-01-04 European Molecular Biology Laboratory Regulation of site-specific recombination by site-specific recombinase/nuclear receptor fusion proteins
JP4216350B2 (ja) * 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター
US5801030A (en) * 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
EP0927263A1 (en) * 1996-01-05 1999-07-07 Genetic Therapy, Inc. Recombinase-mediated generation of adenoviral vectors

Also Published As

Publication number Publication date
US6630322B1 (en) 2003-10-07
ATE301721T1 (de) 2005-08-15
EP0906443A1 (fr) 1999-04-07
CZ296600B6 (cs) 2006-04-12
DE69733948T2 (de) 2006-06-08
CA2257916A1 (fr) 1997-12-18
FR2749857B1 (fr) 1998-08-14
BR9709700A (pt) 1999-08-10
DE69733948D1 (de) 2005-09-15
NO985739D0 (no) 1998-12-08
EP0906443B1 (fr) 2005-08-10
FR2749857A1 (fr) 1997-12-19
ES2248849T3 (es) 2006-03-16
DK0906443T3 (da) 2005-12-19
WO1997047757A1 (fr) 1997-12-18
JP2000511779A (ja) 2000-09-12
HUP9902585A3 (en) 2001-11-28
CZ402398A3 (cs) 1999-03-17
SK169898A3 (en) 1999-07-12
AU3037797A (en) 1998-01-07
NO985739L (no) 1998-12-08
HUP9902585A2 (hu) 1999-11-29
HU224175B1 (hu) 2005-06-28
IL127430A0 (en) 1999-10-28
AU726442B2 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
ZA988124B (en) Mage-3 peptides presented by HLA class II molecules
DE69635931D1 (de) Komplementäre adenovirenvektorsysteme und zellinien
HU9603155D0 (en) Papillomavirus vaccines
IL113955A0 (en) The cytoplasmic inhibition of gene expression
MY140593A (en) 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
IL181695A0 (en) Methods for cultivating cells and propagating viruses
EP1163359A4 (en) PROCESS FOR PRODUCING TRANSCRIPTIONALLY ACTIVE DNA FRAGMENTS
DK0906443T3 (da) Generering af replikerende molekyler in vivo
IL135983A0 (en) Adenovirus vectors and method for reducing homologous recombination phenomena
EP1123414A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF INTEGRIN ALPHA 4
MX9606599A (es) Procedimiento para llevar a cabo un inmunoensayo en un sistema de multiples fases.
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
WO2002097056A3 (en) Method for generating replication defective viral vectors that are helper free
NZ510154A (en) A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
EP0948512A4 (en) METHOD FOR SYNTHESIZING OLIGONUCLEOTIDES PHOSPHOROTHIOATES
DE69834283D1 (de) Vorrichtung zur Zurückgewinnung, Raffination und Speicherung von Wasserstoffgas
EP1457586A4 (en) DEVICE FOR GENERATING F2-GAS AND METHOD FOR GENERATING F2-GAS AND F2-GAS
AP2000001954A0 (en) Heat treated fischer-tropsch catalyst particles.
WO1998018950A3 (de) Aav-dna mit helfervirus-sequenzen
WO1996018737A3 (de) Vektoren und viren zur gentherapie
ZA200307708B (en) Method and apparatus for generating context-descriptive messages.
AU1491499A (en) Cloning method by multiple digestion, vectors for implementing same and applications
EP1185306A4 (en) USE OF VIRAL VECTORS AND LOADED MOLECULES FOR GENE THERAPY
HK1039635B (zh) 一種新的谷氨酰胺酶及其基因和生產方法